Top

International Ophthalmology

Published in:

01-04-2021 | Conjunctivitis | Original Paper

Evaluation of ocular symptoms in COVID-19 subjects in inpatient and outpatient settings

Authors: Betül İlkay Sezgin Akçay, Esra Kardeş, Gülünay Kıray, Betül Ayaz, Gülay Karakuş Hacıoğlu, Emin Pala

Published in: International Ophthalmology | Issue 4/2021

Abstract

Purpose

Evaluation of subtle ocular involvement and clinically significant conjunctivitis symptoms in a group of patients with COVID-19 in outpatient and inpatient settings.

Method

Overall, 1083 patients infected with SARS-CoV-2 were recruited as subjects. Patients were divided into inpatients (group 1, n = 371) and outpatients (group 2, n = 712). Demographical and general medical data included age, sex, and comorbidities. Patients whose diagnosis was confirmed by reverse-transcriptase polymerase chain reaction (RT-PCR) were called by phone, and their chronic ocular disease, previous ocular surgery, ocular medication, contact lens wear and ocular irritation symptoms were queried during the active disease period.

Results

The mean age of the patients was 44.2 ± 16.5 (19–97) years; 635 (58.6%) were male, and 448 (41.4%) were female. Comorbidity, chronic ocular disease, ophthalmic medication and previous ocular surgery rates were significantly higher in group 1 (p < 0.05), while contact lens wear was not significantly different between groups. The main complaints received from patients were sore eye or burning sensation, foreign body sensation, itching and red eye and were significantly higher in group 1. Clinically significant conjunctivitis symptoms, such as red eye, ocular discharge and eyelid edema, were observed in 28 patients (2.6%), with 14 (3.8%) patients in group 1 and 14 (2%) patients in group 2.

Conclusion

Clinically significant conjunctivitis symptoms were detected in 28 subjects in the inpatient and outpatient groups. As systemic findings of COVID-19 intensify,

Wang C, Horby PW, Hayden FG, Gao GF (2020) A novel coronavirus outbreak of global health concern. Lancet 395(10223):470–473. https://doi.org/10.1016/S0140-6736(20)30185-9CrossRefPubMedPubMedCentral

Gu J, Han B, Wang J (2020) COVID-19: gastrointestinal manifestations and potential fecal-oral transmission. Gastroenterology 19:0016–5085. https://doi.org/10.1053/j.gastro.2020.02.054CrossRef

Guan WJ, Ni ZY, Hu Y et al (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. https://doi.org/10.1056/NEJMoa2002032CrossRefPubMedPubMedCentral

Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A et al (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically-proven protease inhibitor. Cell. https://doi.org/10.1016/j.cell.2020.02.052CrossRefPubMedPubMedCentral

Baig AM, Khaleeq A, Ali U, Syeda H (2020) (2020): Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci 11:995–998. https://doi.org/10.1021/acschemneuro.0c00122CrossRefPubMed

Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q (2020) Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 367:1444–1448. https://doi.org/10.1126/science.abb2762CrossRefPubMedPubMedCentral

Holappa M, Vapaatalo H, Vaajanen A (2020) Many faces of renin-angiotensin system-focus on eye. Open Ophthalmol J 11:122. https://doi.org/10.2174/1874364101711010122CrossRef

Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H (2004) Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 203(2):631–637. https://doi.org/10.1002/path.1570CrossRefPubMedPubMedCentral

Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, Li T, Chen Q (2020) High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci 12(1):8. https://doi.org/10.1038/s41368-020-0074-xCrossRefPubMedPubMedCentral

10.

Napoli PE, Nioi M, d’AlojaE FM (2020) The ocular surface and the coronavirus disease 2019: does a dual ‘ocular route’ exist? Clin Med 9:1269. https://doi.org/10.3390/jcm9051269CrossRef

11.

Ministry of Health (2020). COVID-19 Guidelines [online]. Website. https://covid19bilgi.saglik.gov.tr/tr/algoritmalar. Accessed 17Apr 2020

12.

Belser JA, Rota PA, Tumpey TM (2013) Ocular tropism of respiratory viruses. Microbiol Mol Biol Rev 77(1):144–156. https://doi.org/10.1128/MMBR.00058-12CrossRefPubMedPubMedCentral

13.

Vabret A, Mourez T, Dina J, van der Hoek L, Gouarin S, Petitjean J, Brouard J, Freymuth F (2005) Human coronavirus NL63, France. Emerg Infect Dis 11(8):1225–1229. https://doi.org/10.3201/eid1108.050110CrossRefPubMedPubMedCentral

14.

Wu P, Duan F, Luo C, Liu Q, Qu X, Liang L, Wu K (2020) Characteristics of ocular findings of patients with coronavirus disease 2019 (COVID-19) in Hubei province. JAMA Ophthalmol, China. https://doi.org/10.1001/jamaophthalmol.2020.1291CrossRef

15.

Xia J, Tong J, Liu M, ShenY GuoD (2020) Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection. J Med Virol. https://doi.org/10.1002/jmv.25725CrossRefPubMedPubMedCentral

16.

Hong N, Yu W, Xia J, Shen Y, Yap M, Wei HW (2020) Evaluation of ocular symptoms and tropism of SARS-CoV-2 in patients confirmed with COVID-19. Acta Ophthalmol. https://doi.org/10.1111/aos.14445CrossRefPubMedPubMedCentral

17.

Shemer A, Einan-Lifshitz A, Itah A, Dubinsky-Pertzov B, Pras E, Hecht I (2020) Ocular involvement in coronavirus disease 2019 (COVID-19): a clinical and molecular analysis. Int Ophthalmol 14:1–8. https://doi.org/10.1007/s10792-020-01592-1CrossRef

18.

Neri P, Pichi F (2020) COVID-19 and the eye immunity lesson learned from the past and possible new therapeutic insights. Int Ophthalmol. 40(5):1057–1060. https://doi.org/10.1007/s10792-020-01389-2CrossRefPubMedPubMedCentral

19.

Nicolò M, Ferro Desideri L, Bassetti M, Traverso CE (2020) Hydroxychloroquine and chloroquine retinal safety concerns during COVID-19 outbreak. Int Ophthalmol 18:1–7. https://doi.org/10.1007/s10792-020-01593-0CrossRef

Title: Evaluation of ocular symptoms in COVID-19 subjects in inpatient and outpatient settings
Authors: Betül İlkay Sezgin Akçay
Esra Kardeş
Gülünay Kıray
Betül Ayaz
Gülay Karakuş Hacıoğlu
Emin Pala
Publication date: 01-04-2021
Publisher: Springer Netherlands
Keywords: Conjunctivitis
Edema
Severe Acute Respiratory Syndrome Coronavirus
SARS-CoV-2
COVID-19
Eye Surgery
Published in: International Ophthalmology / Issue 4/2021
Print ISSN: 0165-5701
Electronic ISSN: 1573-2630
DOI: https://doi.org/10.1007/s10792-021-01728-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Evaluation of ocular symptoms in COVID-19 subjects in inpatient and outpatient settings

Abstract

Purpose

Method

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Method

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2021

Autologous neurosensory retinal transplantation for large refractory idiopathic macular hole

Endogenous endophthalmitis in patients with intravenous opioid use: demographics and associated comorbidities

Retinal layers in prolactinoma patients: a spectral-domain optical coherence tomography study

Comparison of home-based pencil push-up therapy and office-based orthoptic therapy in symptomatic patients of convergence insufficiency: a randomized controlled trial

Teprotumumab (Tepezza): from the discovery and development of medicines to USFDA approval for active thyroid eye disease (TED) treatment

Outcomes of combined gonioscopy-assisted transluminal trabeculotomy and goniosynechialysis in primary angle closure: a retrospective case series